Analyst Corner – GlaxoSmithKline Pharma: Maintain ‘add’ with revised TP of Rs 1,575

By: |
April 3, 2021 4:15 AM

We expect this trend in recovery in the acute therapies to continue in the coming quarters. GSKP’s exposure only to domestic formulations, strong balance sheet and strong brand equity augurs well. Maintain ADD with a revised target price of Rs 1,575/share (earlier: Rs 1,565/share).

In a prudent decision, GSKP impaired the asset to the tune of Rs6.4bn in its Dec’20 quarterly results and was exploring all options for the plant including sale.In a prudent decision, GSKP impaired the asset to the tune of Rs6.4bn in its Dec’20 quarterly results and was exploring all options for the plant including sale.

GlaxoSmithKline Pharmaceuticals’s (GSKP) has announced the sale of its Vemgal plant located in Karnataka to Hetero Labs Ltd for a cash consideration of Rs1.8bn. Post discontinuation of Zinetac last year this plant remained unutilized and GSKP had announced a write-off on it. Company’s recent financial performance was healthy led by recovery in its key brands and supported by recently launched products (Fluarix Tetra, Menveo and Nucala).

We expect this trend in recovery in the acute therapies to continue in the coming quarters. GSKP’s exposure only to domestic formulations, strong balance sheet and strong brand equity augurs well. Maintain ADD with a revised target price of Rs 1,575/share (earlier: Rs 1,565/share).

Hetero buys Vemgal plant. GSKP announced sale of its newly constructed manufacturing plant at Vemgal, Karnataka along with the land, plant and machinery, assets, software and equipment to Hetero Labs for a cash consideration of Rs 1.8bn. The agreement is expected to complete within the next five days, however, transaction is expected to complete by Sep’21 post necessary approvals and formalities. GSKP had intended to use ~60% of the manufacturing capability towards Zinetac (ranitidine), however, after the NDMA impurity issue, GSKP stopped its manufacturing and sale of the product in Sep’20. This would lead to severe underutilisation of the Vemgal plant which was yet to commercialise. In a prudent decision, GSKP impaired the asset to the tune of Rs 6.4bn in its Dec’20 quarterly results and was exploring all options for the plant including sale.

Financial impact. Post the impairment, the book value of the asset that was market for sale stood at Rs 3.75bn. The sale is announced for a cash consideration of Rs1.8bn. Hence, post the transaction, GSKP would record a loss of Rs1.95bn. The transaction would remove unutilised asset and improve return ratios Since, the company stopped manufacturing Zinetac at its existing plant in Nashik, there is no immediate requirement for a new plant limiting the capex requirement. GSKP may announce higher dividend in FY22E to utilise its surplus cash after FCF of Rs 5.4bn in FY21E and additional cash inflow of Rs 1.8bn post the transaction.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Last hour surge lifts Sensex, Nifty on weekly expiry day; here’s what analysts make of today’s trade
2Reliance Industries top laggard for Mutual Funds in March; fund managers sell nearly 90 lakh shares
3Bernie Madoff, architect of $65 billion Ponzi scheme, dies in prison: How he deceived people